Identification of stronger associations between acrylamide and ovarian cancer in genetically susceptible individuals (e.g., of a certain CYP2E1 genotype) increases confidence that the observed association between acrylamide intake and ovarian cancer is not due to chance or bias. This evidence concerns the gene CYP2E1 and ovarian cancer.